新加坡：卫生当局周五（10月2日）表示，九价人乳头瘤病毒（HPV9）疫苗将于明年被纳入国家免疫计划，为符合条件的新加坡女性公民和永久居民提供更广泛的宫颈癌防护。
SINGAPORE: The human papillomavirus 9-valent (HPV9) vaccine will be added to national immunisation schedules next year, health authorities said on Friday (Oct 2), giving eligible female Singaporeans and permanent residents broader protection against cervical cancer.
新加坡卫生部（MOH）、保健促进局（HPB）和传染病局（CDA）在联合新闻稿中宣布，自2027年1月1日起，HPV9疫苗将被纳入国家儿童免疫计划（NCIS）、国家成人免疫计划（NAIS）以及受补贴疫苗清单（SVL）。
From Jan 1, 2027, the HPV9 vaccine will be added to the National Childhood Immunisation Schedule (NCIS), National Adult Immunisation Schedule (NAIS) and Subsidised Vaccine List (SVL), said the Ministry of Health (MOH), Health Promotion Board (HPB) and Communicable Diseases Agency (CDA) in a joint release.
当局表示：“九价HPV疫苗（又称Gardasil 9）将被纳入9至26岁女性的NCIS和NAIS计划中。二价HPV疫苗（又称Cervarix）将作为替代选项保留在上述两个计划中。”人乳头瘤病毒（HPV）是全球最常见的性传播感染，近80%的男性和女性在其一生中都会感染。它不仅会导致宫颈癌，还可能引发肛门癌、喉癌、外阴癌、阴道癌和阴茎癌。在新加坡，建议9至26岁的女性接种HPV疫苗以预防宫颈癌。
“The HPV9 vaccine, also known as Gardasil 9, will be included in the NCIS and NAIS for females aged 9 to 26,” said the authorities. “The HPV2 vaccine, also known as Cervarix, will remain on both schedules as an alternative option.”Human papillomavirus, or HPV, is the most common sexually transmitted infection worldwide, with nearly 80 per cent of men and women infected at some point in their lives. It can cause cervical cancer, as well as cancers of the anus, throat, vulva, vagina and penis. In Singapore, HPV vaccination is recommended for females aged 9 to 26 for the prevention of cervical cancer.
卫生部、保健促进局和传染病局周五表示：“二价和九价HPV疫苗均可预防导致70%宫颈癌的HPV 16型和18型病毒。”
“Both the HPV2 and HPV9 vaccines protect against HPV types 16 and 18, which cause 70 per cent of all cervical cancers,” said MOH, HPB and CDA on Friday.
“九价HPV疫苗提供了更广泛的保护，它还覆盖了导致另外20%宫颈癌的HPV病毒类型，使其总覆盖率达到约90%。”根据更新后的建议，未接种疫苗的女性可以选择接种二价或九价HPV疫苗来开始接种程序。
“The HPV9 vaccine provides broader protection by also covering additional HPV types that account for a further 20 per cent of cervical cancers, bringing its total coverage to approximately 90 per cent.”Under the updated recommendations, unvaccinated females may start their vaccination series with either HPV2 or HPV9.
建议9至14岁首次接种者接种两剂，15至26岁首次接种者接种三剂。
Two doses are recommended for those receiving their first dose from age 9 to 14, while three doses are recommended for those receiving their first dose from age 15 to 26.
当局指出，如果HPV疫苗接种在26岁之前开始但未完成，剩余剂次可在26岁之后尽快补种，最迟可接种至45岁。
If HPV vaccination is started but not completed by age 26, the remaining doses may be taken after age 26, as soon as possible and up to age 45, said the authorities.
对于已开始接种HPV2或HPV4疫苗但尚未完成全程接种的女性，可改用HPV9疫苗来完成接种程序。此前被称为“Gardasil”的HPV4疫苗现已不再在新加坡销售，并已被从国家免疫计划及国家成人免疫计划中剔除。
Females who started their vaccination series with HPV2 or HPV4 and have remaining doses may complete the series with HPV9. HPV4, previously known as Gardasil, is no longer available in Singapore and has been removed from the NCIS and NAIS.
新加坡卫生部、健康促进局及牙科协会表示：“多项研究证实，这种混合使用不同HPV疫苗的接种方案是安全的，能够有效预防两种疫苗所覆盖的所有HPV亚型。”
“Studies have shown that such mixed HPV vaccination schedules are safe and provide protection against the HPV strains covered by both vaccines,” said MOH, HPB and CDA.
对于已完成推荐HPV疫苗接种程序的人群，不建议再额外接种HPV9疫苗。
Those who have completed their recommended HPV vaccination schedules are not recommended to receive additional HPV9 doses.
根据健康促进局推行的校园HPV疫苗接种计划，中学一年级和二年级的女学生均可免费接种HPV疫苗。自2027年1月1日起，该计划中将以HPV9取代HPV2用于尚未开始或尚未完成接种的女学生。2026年入学的中学一年级女生若已接种了第一剂HPV2疫苗，则将于2027年接种HPV9作为第二剂。
HPV9 REPLACES HPV2 IN SCHOOLS Under HPB’s school-based HPV vaccination programme, Secondary 1 and 2 female students are offered HPV vaccination at no charge. From Jan 1, 2027, HPV9 will replace HPV2 for female students who have yet to start or complete their vaccination series under the programme. Female students in the 2026 Secondary 1 cohort who received HPV2 as their first dose will receive HPV9 as their second dose in 2027.
据卫生部官网介绍，HPV2疫苗仅适用于女性接种，而HPV9疫苗则男女均可接种。目前，政府尚未为HPV9疫苗接种提供补贴，也无法通过医疗储蓄账户支付相关费用。
According to MOH's vaccination website, HPV2 ised for use in females, while HPV9 ised for both females and males. Government subsidies and MediSave are currently not available for HPV9 vaccination.
以新加坡妇女诊所为例，根据其官网信息，目前HPV9疫苗的单剂费用高达250新元（约合195美元），是HPV2疫苗单剂费用（96新元）的两倍多。
At Singapore Women's Clinic, for example, HPV9 currently costs more than twice as much as HPV2, at S$250 (US$195) per dose compared with S$96 per dose, according to its website.
自2027年1月1日起，符合条件的新加坡儿童可在社区家庭医生诊所及综合诊疗所享受HPV9疫苗接种的全额补贴；符合条件的新加坡成年人则可在这些医疗机构享受最高75%的按收入情况分级发放的补贴。符合条件的永久居民也可在综合诊疗所获得相应补贴。
From Jan 1, 2027, eligible Singaporean children will receive full subsidies for HPV9 vaccination at CHAS GP clinics and polyclinics, while eligible Singaporean adults can receive means-tested subsidies of up to 75 per cent at these settings. Eligible permanent residents can receive subsidies at polyclinics.
同样从2027年1月1日起，符合接种条件的群体在接种HPV9疫苗时也可使用医疗储蓄账户支付费用，但需遵守现行医疗储蓄账户用于慢性病及预防保健治疗的提取限额规定。
MediSave use will also be extended to HPV9 vaccination for people in the recommended groups from Jan 1, subject to the prevailing MediSave Chronic and Preventive Care withdrawal limits.
对于已完成建议剂次的人群，接种额外剂次的九价人乳头瘤病毒（HPV9）疫苗将不再适用疫苗补贴及保健储蓄（MediSave）支付。
Vaccination subsidies and MediSave use will not be applicable to additional doses of the HPV9 vaccine for those who have already completed the recommended doses.
符合条件的人士可通过 vaccine.gov.sg 预约参与计划的社区健康援助计划（CHAS）全科诊所，或直接向综合诊疗所预约接种。更新后的九价HPV疫苗接种计划将于1月1日起生效。
Eligible individuals can book HPV vaccination appointments at participating CHAS GP clinics through vaccine.gov.sg or make an appointment at polyclinics. HPV9 vaccination under the updated schedules will be available from Jan 1.